{"Clinical Trial ID": "NCT03176238", "Intervention": ["INTERVENTION 1:", "- Asian Everolimus + Exemestane", "Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once daily Participants in Asian countries: Indonesia, India, Vietnam, Turkey, South Korea, Thailand, Malaysia, Taiwan or Jordan.", "INTERVENTION 2:", "Non-Asian Everolimus + Exemestane", "Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once daily Participants in non-Asian countries: Australia, Morocco, South Africa or Tunisia."], "Eligibility": ["Incorporation criteria:", "Menopausal women with metastatic, recurrent or locally advanced breast cancer cannot receive curative surgery or radiation therapy.", "- Histological or cytological confirmation of hormone-receptor positive breast cancer (HR+).", "- Nonsteroidal aromatase inhibitors refractory diseases, defined as:", "Recurrence during or within 12 months (365 days) after the end of the adjuvant therapy with letrozole or anastrozole, or", "\u2022 Progression during or within one month (30 days) after completion of letrozole or anastrozole therapy for locally advanced or metastatic breast cancer (CBA).", "Radiological or objective evidence of recurrence or progression during or after the last systemic treatment prior to registration.", "Patients should have:", "At least one injury that could have been accurately measured in at least one dimension", "20 mm with conventional imaging techniques or 10 mm with spiral MRI, or", "Bone injury: lytic or mixed (lytic + blast) in the absence of measurable disease as defined above.", "A proper bone marrow, coagulation, liver and kidney function.", "\u00b7 ECOG Performance Status 2.", "- Exclusion criteria:", "Patients with HIC 2+ should undergo a negative in situ hybridization test.", "* Patients with only unmeasurable lesions other than bone metastases (e.g. pleural effusion, ascites).", "One line of chemotherapy is an anticancer treatment containing at least 1 cytotoxic chemotherapy agent, administered for at least 21 days.", "Previous treatment with mTOR inhibitors.", "\u2022 Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin).", "Patients with a known history of HIV seropositivity do not need to be screened for HIV infection at baseline.", "* Patients treated with medicinal products known to be potent inhibitors or inducers of CYP3A isoenzyme", "\u2022 History of CNS brain or other metastases, including leptomeningal metastases."], "Results": ["Performance measures:", "Summary of Number of Participants with Emerging Adverse Reactions to Treatment (EET) - All Classes", "While a patient may have had two or more adverse events, the patient is only counted once in one category.", "Time frame: Baseline up to about 43 weeks for Asian countries and 32 weeks for non-Asian countries, including a 30-day follow-up period after treatment", "Results 1:", "Title of the arm/group : \u00c9verolimus asian + Exemestane", "Description of the arm/group: Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once a day. Participants in Asian countries: Indonesia, India, Vietnam, Turkey, South Korea, Thailand, Malaysia, Taiwan or Jordan.", "Total number of participants analysed: 199", "Type of measure: Number of participants", "Unit of measure: Non-TEAE participants: 4 2.0%", "At least 1 EAE: 195 98.0%", "At least 1 drug-related EAE: 185 93.0%", "At least 1 serious EAET (STEAE): 59 29.6%", "STEAE leading to death: 6 3,0 %", "Non-fatal STEAE: 53 26.6%", "At least 1 drug-related AETS: 28 14.1%", "At least 1 drug-related AETS - death: 2 1.0%", "At least 1 non-dead drug-related AETS: 26 13.1%", "TEAE leading to permanent shutdown tx: 25 12.6%", "- TE AESI: 172 86,4 %", "Results 2:", "Title of the arm/group : Everolimus non asian + Exemestane", "Description of the arm/group: Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once daily Participants in non-Asian countries: Australia, Morocco, South Africa or Tunisia.", "Total number of participants analysed: 36", "Type of measure: Number of participants", "Unit of measure: Non-TEAE participants: 0 0.0%", "At least 1 EAE: 36 100.0%", "At least 1 drug-related EAE: 33 91.7%", "At least 1 serious EAET (STEAE): 16 44.4%", "STEAE leading to death: 4 11.1%", "Non-fatal STEAE: 12 33.3%", "At least 1 drug-related AETS: 8 22.2%", "At least 1 drug-related AETS - death: 1 2.8%", "At least 1 non-dead drug-related EAETS: 7 19.4%", "TEAE leading to permanent discontinuation of treatment: 11 30.6 %", "- TE AESI: 34 94,4 %"], "Adverse Events": ["Undesirable Events 1:", "Total: 59/199 (29.65%)", "Anemia 7/199 (3.52%)", "Thrombocytopenia 2/199 (1.01%)", "- Acute myocardial infarction 0/199 (0.00 %)", "Atrial fibrillation 1/199 (0.50%)", "Cardiac arrest 1/199 (0.50%)", "1/199 (0.50%)", "Cardiopulmonary impairment 1/199 (0.50%)", "1/199 (0.50%) left ventricular failure", "- Superventricular tachycardia 0/199 (0.00 %)", "1/199 (0.50%)", "Adverse Events 2:", "Total: 16/36 (44.44 per cent)", "Anemia 2/36 (5.56%)", "Thrombocytopenia 1/36 (2.78%)", "Acute myocardial infarction 1/36 (2.78 %)", "Atrial fibrillation 0/36 (0.00 %)", "Cardiac arrest 0/36 (0.00 %)", "Heart failure 0/36 (0.00 %)", "Cardiopulmonary failure 0/36 (0.00 %)", "- Left ventricular failure 0/36 (0.00 %)", "1/36 (2.78 %)", "- Ventricular tachycardia 0/36 (0.00 %)"]}